WebFeb 7, 2024 · Trodelvy is a first-in-class antibody and topoisomerase inhibitor conjugate directed to the TROP-2 receptor, a protein overexpressed in multiple types of epithelial tumors, including metastatic ... WebSep 7, 2024 · Trodelvy ® (sacituzumab govitecan-hziy) is a first-in-class Trop-2 directed antibody-drug conjugate. Trop-2 is a cell surface antigen highly expressed in multiple tumor types, including in more than 90% of breast and bladder cancers.
Trodelvy (sacituzumab govetecan) Treatment for Triple Negative …
WebFeb 7, 2024 · TRODELVY (sacituzumab govitecan-hziy) for injection is a sterile, preservative-free, off-white to yellowish lyophilized powder for intravenous use in a 50 mL clear glass single-dose vial, with a rubber … WebOct 15, 2024 · Trodelvy’s active ingredient is sacituzumab govitecan. It combines a humanised antibody (a type of protein) designed to recognise and attach to the Trop-2 receptor with a type of an antineoplastic agent called topoisomerase I inhibitor. This is intended to inhibit the cancer to grow, divide and spread. pictures of horses head
Trodelvy: Package Insert - Drugs.com
WebTRODELVY is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with: To Locally Advanced or Metastatic Breast Cancer … WebOct 31, 2024 · Trodelvy (sacituzumab govitecan-hziy) is a chemotherapy drug used to treat certain triple-negative breast cancers (TNBC) and urothelial cancers (a type of bladder cancer).It is used to treat patients with a poor prognosis and limited treatment options who have already been treated with other therapies and who have advanced tumors or tumors … WebTRODELVY ® (sacituzumab govitecan-hziy) is a prescription medicine used to treat adults with: hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread … pictures of horse heads to draw